An observational study in Human Papilloma Virus Infection and Pterygium, sponsored by Chulalongkorn University. Completed at 1 site in Thailand. Per ClinicalTrials.gov, last updated 2020-07-14.
Sponsored by Chulalongkorn University · Observational
Prevalence of HPV-associated eye infection and cytokine levels in tears from patients diagnosed with pterygium
The main purpose of this study is to evaluate the prevalence of HPV infection in primary and recurrent pterygium and the association of HPV types collecting from conjunctiva swab and urine. The second purpose is to compare a quantity of cytokines including IL-6, IL-18 and growth factor including VEGF found in tears of patients with primary and recurrent pterygium to participants with free of ocular disease Primary hypothesis
Secondary hypothesis
576 studies on the registry are indexed under Papillomavirus Infections; 132 are open to participants now.
This study's enrollment of 141 is below the median of 490 across 157 observational studies indexed under Papillomavirus Infections.
Browse Papillomavirus Infections studies →Chulalongkorn University is the lead sponsor of 322 studies on the registry; 66 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Population:Patients diagnosed with primary pterygium and recurrent pterygium Target Population: Patients diagnosed with primary pterygium at out-patient clinic, Department of Ophthalmology, King Chulalongkorn Memorial Hospital Control Population: participants without any ocular diseases
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants as primary and secondary pterygium group
Inclusion Criteria:
Exclusion Criteria:
Participant without ocular disease Inclusion criteria
Participants who was diagnosed with primary pterygium
Diagnostic Test: HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) · Diagnostic Test: Bio-Plex® 200 system (Bio- Rad, Hercules, CA)
Participants who was diagnosed with secondary pterygium
Diagnostic Test: HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) · Diagnostic Test: Bio-Plex® 200 system (Bio- Rad, Hercules, CA)
Participants who have no pterygium and other inflammation disease in eyes
Diagnostic Test: HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) · Diagnostic Test: Bio-Plex® 200 system (Bio- Rad, Hercules, CA)
HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) for swab sample collected from pterygium and normal conjunctiva and also for urine collected in Colli-PeeTM device (Novosanis, Belgium)
Bioplex was use for measure cytokine IL-6, IL-18 and VEGF from tears collected from Schirmer strip
HPV prevalence
1. To compare HPV prevalence in subjects with primary pterygium and with recurrent pterygium
Time frame: 1 hour per participants which is on a day for collecting sample
HPV autoinoculation
To assess whether HPV autoinoculation is present, we evaluate whether there is an association between HPV ocular infection and genital infection.
Time frame: 1 hour per participants which is on a day for collecting sample
cytokine IL-6, IL-18 and VEGF levels
To compare cytokine IL-6, IL-18 and VEGF levels among various subgroups, including recurrent pterygium subjects with HPV positive and HPV negative status, primary pterygium subjects with HPV positive and HPV negative, and subjects without ocular diseases
Time frame: 1 hour per participants which is on a day for collecting sample
Plan to share: Yes — If there is anybody contacting our team for data in the purpose of future research, we agree to share our data.
Supporting information: Study protocol, Clinical study report
Time frame: 1 year after published
No publications or documents are linked to this record.
Ran from Jan 2020 to primary completion in Apr 2020, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.